1-4 of 4
Harald Sommer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis

Wolfgang Janni, Florian D. Vogl, Gro Wiedswang, Marit Synnestvedt, Tanja Fehm, Julia Jückstock, Elin Borgen, Brigitte Rack, Stephan Braun, Harald Sommer, Erich Solomayer, Klaus Pantel, Jahn Nesland, Klaus Friese, Bjørn Naume
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2967–2976.
https://doi.org/10.1158/1078-0432.CCR-10-2515
Published: 01 May 2011
View article titled, Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis
Open the PDF for Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis in another window
Includes: Supplementary data
Journal Articles

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

Alexander Burges, Pauline Wimberger, Carolin Kümper, Vera Gorbounova, Harald Sommer, Barbara Schmalfeldt, Jacobus Pfisterer, Michail Lichinitser, Anatoliy Makhson, Vladimir Moiseyenko, Angelika Lahr, Elisabeth Schulze, Michael Jäger, Michael A. Ströhlein, Markus Maria Heiss, Thomas Gottwald, Horst Lindhofer, Rainer Kimmig
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3899–3905.
https://doi.org/10.1158/1078-0432.CCR-06-2769
Published: 02 July 2007
View article titled, Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study
Open the PDF for Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study in another window
Journal Articles

Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert, Maja Heinrigs, Brigitte Rack, Alexander Marmé, Agnieszka Korfel, Michael Jäger, Horst Lindhofer, Harald Sommer, Eckhard Thiel, Michael Untch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3085–3091.
https://doi.org/10.1158/1078-0432.CCR-05-2436
Published: 17 May 2006
View article titled, Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer
Open the PDF for Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer in another window
Journal Articles

Safety and Immunogenicity of TA-HPV, a Recombinant Vaccinia Virus Expressing Modified Human Papillomavirus (HPV)-16 and HPV-18 E6 and E7 Genes, in Women with Progressive Cervical Cancer

Andreas M. Kaufmann, Peter L. Stern, Elaine M. Rankin, Harald Sommer, Volkmar Nuessler, Achim Schneider, Malcom Adams, Toli S. Onon, Thomas Bauknecht, Uwe Wagner, Karlijn Kroon, Julian Hickling, Christopher M. Boswell, Simon N. Stacey, Henry C. Kitchener, Jennifer Gillard, Jantien Wanders, John St. C. Roberts, Heinz Zwierzina
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3676–3685.
Published: 01 December 2002
View article titled, Safety and Immunogenicity of TA-HPV, a Recombinant Vaccinia Virus Expressing Modified Human Papillomavirus (HPV)-16 and HPV-18 <em>E6</em> and <em>E7</em> Genes, in Women with Progressive Cervical Cancer
Open the PDF for Safety and Immunogenicity of TA-HPV, a Recombinant Vaccinia Virus Expressing Modified Human Papillomavirus (HPV)-16 and HPV-18 <em>E6</em> and <em>E7</em> Genes, in Women with Progressive Cervical Cancer in another window